5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner (Q44100868)

From Wikidata

Jump to navigation Jump to search

scientific article published in August 2002

Language	Label	Description	Also known as
English	5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner	scientific article published in August 2002

Statements

scholarly article

1 reference

Europe PubMed Central

29 November 2017

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner (English)

1 reference

Europe PubMed Central

29 November 2017

nucleus accumbens

1 reference

based on heuristic

inferred from title

author name string

Jean-François Liégeois

1

1 reference

Europe PubMed Central

29 November 2017

Junji Ichikawa

2

1 reference

Europe PubMed Central

29 November 2017

Herbert Y Meltzer

3

1 reference

Europe PubMed Central

29 November 2017

language of work or name

0 references

publication date

1 August 2002

1 reference

Europe PubMed Central

29 November 2017

1 reference

Europe PubMed Central

29 November 2017

947

1 reference

Europe PubMed Central

29 November 2017

2

1 reference

Europe PubMed Central

29 November 2017

157-165

1 reference

Europe PubMed Central

29 November 2017

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

(R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Catecholamine modulation of prefrontal cortical cognitive function

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride — an123I-IBZM single photon emission tomography (SPET) study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Increase of dialysate dopamine in the bed nucleus of stria terminalis by clozapine and related neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Dopamine in schizophrenia: a review and reconceptualization

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The anxiolytic serotonin 5-HT1A receptor agonists buspirone, ipsapirone and gepirone are inhibitors of tyrosine hydroxylation in rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

5-HT2 antagonism and EPS benefits: is there a causal connection?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Serotonin-dopamine interaction and its relevance to schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Dopamine D(2) receptor blockade by haloperidol. (3)H-raclopride reveals much higher occupancy than EEDQ.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Dopamine, the prefrontal cortex and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

R(+)-8-OH-DPAT, a selective 5-HT(1A) receptor agonist, attenuated amphetamine-induced dopamine synthesis in rat striatum, but not nucleus accumbens or medial prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Increased dopamine transmission in schizophrenia: relationship to illness phases

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT(2A) and 5-HT(2C) receptor subtypes and significance of the haloperidol dose used

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The dopamine hypothesis of schizophrenia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The role of serotonin in antipsychotic drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

An atypical compound by any other name is still a

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride?: PET studies combined with microdialysis in conscious monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Differential effects of dopamine antagonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2902620-3

7 January 2021

Identifiers

10.1016/S0006-8993(02)02620-3

1 reference

Europe PubMed Central

29 November 2017

1 reference

Europe PubMed Central

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44100868&oldid=2106595513"